Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00064623
Recruitment Status : Completed
First Posted : July 11, 2003
Last Update Posted : March 6, 2008
Information provided by:

Brief Summary:
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is effective in treating painful HIV-associated neuropathy.

Condition or disease Intervention/treatment Phase
HIV Infections Peripheral Nervous System Diseases Pain Drug: Capsaicin Dermal Patch Phase 3

Detailed Description:

The C107 study is a randomized, double-blind, controlled dose finding study of NGX-4010 for the treatment of painful symptoms of HIV-associated neuropathy. Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and to receive double-blind NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin).

Participants who complete study evaluations through Week 12 will have the option of receiving up to 3 additional open-label treatments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy
Study Start Date : August 2003
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Capsaicin

Primary Outcome Measures :
  1. Percent change from baseline in the "average pain for the past 24 hours" Numeric Pain Rating Scale (NPRS) score (i.e., average of scores during Weeks 2-12, compared to baseline)

Secondary Outcome Measures :
  1. Percent change from baseline in the "average pain for the past 24 hours" NPRS score (i.e., average of scores during Weeks 2-4 and 2-8, respectively, compared to baseline)
  2. Proportion of subjects reaching 30% decrease from baseline in their "average pain for the past 24 hours" NPRS scores on average during Weeks 2-12, within each treatment group
  3. Proportion of subjects reaching 30% decrease from baseline in their "average pain for the past 24 hours" NPRS scores on average during Weeks 2-4 and 2 8, respectively, within each treatment group
  4. Percent change from baseline in the "worst pain for the past 24 hours" and "pain now" NPRS scores (baseline score compared to the average of scores from Weeks 2 -12), within each treatment group
  5. "Pain now" on evening of treatment day
  6. Mean onset and duration of efficacy in days within each treatment group
  7. Proportion of subjects with significant changes in concomitant pain medication usage during Weeks 2-12, compared to baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age
  • Documented evidence of HIV-1 infection
  • Documented diagnosis of painful HIV-associated distal symmetrical polyneuropathy established by a neurologist resulting from HIV disease and/or antiretroviral drug exposure, with primary symptoms of pain, burning or dysesthetic discomfort in both feet for at least 2 months prior to Screening Visit, and absent or diminished ankle reflexes, and at least one of the following: distal diminution of vibration sensation or pain or temperature sensation in the legs
  • Either no neurotoxic antiretroviral (didanosine, zalcitabine or stavudine) exposure for at least 8 weeks prior to Screening Visit, or currently on stable dose(s) of any neurotoxic antiretroviral(s) for at least 8 weeks prior to Screening Visit
  • Screening Pain Sum Score of 12 to 36
  • Karnofsky Performance Score of greater than or equal to 60
  • Intact, unbroken skin over the painful area(s) to be treated
  • If taking chronic pain medications, be on a stable (not PRN) regimen for at least 21 days prior to Treatment Visit and willing to maintain these medications at the same stable dose(s) and schedule throughout the study
  • Female subjects with child-bearing potential: negative serum pregnancy test performed at Screening Visit
  • Willing to use effective methods of birth control and/or refrain from participating in a conception process during study and for 30 days following experimental drug exposure
  • Willing and able to comply with protocol requirements for duration of study

Exclusion Criteria:

  • Concomitant opioid medication, unless orally or transdermally administered and not exceeding a total daily dose of morphine 60 mg/day, or equivalent. Parenteral opioid use is excluded, regardless of dose
  • Unavailability of an effective rescue medication strategy for the subject, such as unwillingness to use opioid analgesics during treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort with Roxicodone® or Vicodin®, as judged by the Investigator
  • Active substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse judged likely to recur during the study period by the investigator
  • Recent use (within 21 days preceding the Treatment Visit of any topically applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics (including Lidoderm®), steroids or capsaicin products on the painful areas
  • Current use of any investigational agent or Class 1 anti-arrhythmic drugs
  • Significant pain of an etiology other than painful HIV-associated neuropathy; significant ongoing pain from other cause(s) that may interfere with judging HIV-associated neuropathy pain
  • Evidence of another contributing cause for peripheral neuropathy, e.g., diabetes mellitus requiring medication control (i.e., oral hypoglycemics, insulin); hereditary neuropathy; vitamin B12 deficiency (B12 level ≤ 200 pg/mL) or less than 3 months of B12 supplementation prior to Screening Visit; or treatment within 90 days prior to Screening Visit with any drug that may have contributed to the sensory neuropathy
  • Any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain
  • Treatment for acute opportunistic infections within 14 days before Treatment Visit
  • Presence of acute, active opportunistic infection, except oral thrush; oral, genital, or rectal herpes; and Mycobacterium avium bacteremia within 2 weeks prior to Screening Visit
  • Currently have active malignant disease
  • Significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or pulmonary function that may interfere either with the ability to complete the study or the evaluation of adverse events
  • Hypersensitivity to capsaicin (i.e., chili peppers or OTC capsaicin products), local anesthetics, Roxicodone®, Vicodin®, or adhesives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00064623

Layout table for location information
United States, Arizona
NeurogesX Investigational Site
Phoenix, Arizona, United States, 85006
NeurogesX Investigational Site
Phoenix, Arizona, United States, 85023
United States, California
NeurogesX Investigational Site
Berkeley, California, United States, 94609
NeurogesX Investigational Site
San Diego, California, United States, 92103
NeurogesX Investigational Site
San Francisco, California, United States, 94117
NeurogesX Investigational Site
Stanford, California, United States, 94305
NeurogesX Investigational Site
West Hollywood, California, United States, 90069
United States, Florida
NeurogesX Investigational Site
Fort Lauderdale, Florida, United States, 33306
NeurogesX Investigational Site
Miami, Florida, United States, 33133
NeurogesX Investigational Site
Miami, Florida, United States, 33136
NeurogesX Investigational Site
North Palm Beach, Florida, United States, 33408
NeurogesX Investigational Site
Orlando, Florida, United States, 32804
NeurogesX Investigational Site
Sunrise, Florida, United States, 33351
NeurogesX Investigational Site
Vero Beach, Florida, United States, 32960
United States, Hawaii
NeurogesX Investigational Site
Honolulu, Hawaii, United States, 96816
United States, Illinois
NeurogesX Investigational Site
Chicago, Illinois, United States, 60612
United States, Kentucky
NeurogesX Investigational Site
Lexington, Kentucky, United States, 40536
United States, Maryland
NeurogesX Investigational Site
Baltimore, Maryland, United States, 21205
United States, Massachusetts
NeurogesX Investigational Site
Boston, Massachusetts, United States, 02215
NeurogesX Investigational Site
Springfield, Massachusetts, United States, 01107
United States, Michigan
NeurogesX Investigational Site
Detroit, Michigan, United States, 48201
United States, Minnesota
NeurogesX Investigational Site
Minneapolis, Minnesota, United States, 55416
United States, Missouri
NeurogesX Investigational Site
St. Louis, Missouri, United States, 63108
United States, New Jersey
NeurogesX Investigational Site
Camden, New Jersey, United States, 08103-1489
United States, New York
NeurogesX Investigational Site
Albany, New York, United States, 12208
NeurogesX Investigational Site
New York, New York, United States, 10021
NeurogesX Investigational Site
New York, New York, United States, 10029
United States, North Carolina
NeurogesX Investigational Site
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
NeurogesX Investigational Site
Cleveland, Ohio, United States, 44106
United States, Oregon
NeurogesX Investigational Site
Portland, Oregon, United States, 97209
United States, Texas
NeurogesX Investigational Site
Austin, Texas, United States, 78705
NeurogesX Investigational Site
Dallas, Texas, United States, 75208
NeurogesX Investigational Site
Houston, Texas, United States, 77030
NeurogesX Investigational Site
San Antonio, Texas, United States, 78229
United States, Wisconsin
NeurogesX Investigational Site
Madison, Wisconsin, United States, 53792-5132
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: David M Simpson, MD Icahn School of Medicine at Mount Sinai
Study Director: Jeffrey Tobias, MD NeurogesX
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00064623    
Other Study ID Numbers: C107
First Posted: July 11, 2003    Key Record Dates
Last Update Posted: March 6, 2008
Last Verified: March 2008
Keywords provided by NeurogesX:
Dermal assessment
Pain measurement
Analgesics/*therapeutic use
Capsaicin/*administration & dosage/adverse effects
HIV Infections/*complications/*drug therapy
Peripheral Nervous System Diseases/*complications/diagnosis/*therapy
Peripheral Nervous System Diseases/drug therapy/*etiology/physiopathology
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Nervous System Diseases
Peripheral Nervous System Diseases
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Neuromuscular Diseases
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs